Prelude Capital Management, LLC Rocket Pharmaceuticals, Inc. Transaction History

Prelude Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$16.78 - $31.94 $342,312 - $651,576	20,400 New	20,400 $611,000
Q1 2020 May 15, 2020	SELL	$9.71 - $25.11 $1,786 - $4,620	-184 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$11.07 - $24.23 $2,036 - $4,458	184 New	184 $4,000
Q3 2019 Nov 14, 2019	SELL	$10.85 - $14.78 $2,213 - $3,015	-204 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$15.0 - $19.81 $690 - $911	46 Added 29.11%	204 $3,000
Q1 2019 May 15, 2019	BUY	$13.45 - $19.01 $40 - $57	3 Added 1.94%	158 $3,000
Q4 2018 Feb 14, 2019	BUY	$11.21 - $23.53 $1,737 - $3,647	155 New	155 $2,000
Q3 2018 Nov 14, 2018	SELL	$18.5 - $25.49 $150,460 - $207,310	-8,133 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$14.58 - $23.0 $118,579 - $187,059	8,133 New	8,133 $160,000

226

96.6M

319K

70.3K

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $746M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.